Chronic Kidney Disease-Pipeline Review, H1 2017

Chronic Kidney Disease-Pipeline Review, H1 2017


  • Products Id :- GMDHC9243IDB
  • |
  • Pages: 195
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Chronic Kidney Disease-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Kidney Disease-Pipeline Review, H1 2017, provides an overview of the Chronic Kidney Disease (Genito Urinary System And Sex Hormones) pipeline landscape.

Chronic kidney disease is the slow loss of kidney function over time. Signs and symptoms of kidney disease include nausea, vomiting, loss of appetite, fatigue and weakness, sleep problems, hiccups and swelling of feet and ankles. The predisposing factors include age, diabetes, high blood pressure, heart disease, smoking, obesity and high cholesterol.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chronic Kidney Disease-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chronic Kidney Disease (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chronic Kidney Disease (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Chronic Kidney Disease (Chronic Renal Failure) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 2, 10, 18, 1, 20 and 5 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 1 molecules, respectively.

Chronic Kidney Disease (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Kidney Disease (Genito Urinary System And Sex Hormones).

The pipeline guide reviews pipeline therapeutics for Chronic Kidney Disease (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Chronic Kidney Disease (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Chronic Kidney Disease (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Kidney Disease (Genito Urinary System And Sex Hormones)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Chronic Kidney Disease (Genito Urinary System And Sex Hormones).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Chronic Kidney Disease (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Chronic Kidney Disease (Chronic Renal Failure)-Overview 8

Chronic Kidney Disease (Chronic Renal Failure)-Therapeutics Development 9

Pipeline Overview 9

Pipeline by Companies 10

Pipeline by Universities/Institutes 14

Products under Development by Companies 15

Products under Development by Universities/Institutes 18

Chronic Kidney Disease (Chronic Renal Failure)-Therapeutics Assessment 19

Assessment by Target 19

Assessment by Mechanism of Action 22

Assessment by Route of Administration 25

Assessment by Molecule Type 27

Chronic Kidney Disease (Chronic Renal Failure)-Companies Involved in Therapeutics Development 29

Angion Biomedica Corp 29

apceth Biopharma GmbH 29

Astellas Pharma Inc 30

AstraZeneca Plc 30

Bayer AG 31

BLR Bio LLC 31

Boehringer Ingelheim GmbH 32

Boryung Pharmaceutical Co Ltd 32

Cellmid Ltd 33

Chugai Pharmaceutical Co Ltd 33

Complexa Inc 34

Corvidia Corp 34

CTI BioPharma Corp 35

Evotec AG 35

F. Hoffmann-La Roche Ltd 36

Gilead Sciences Inc 36

GNI Group Ltd 37

Lupin Ltd 37

Navya Biologicals Pvt Ltd 38

Nippon Zoki Pharmaceutical Co Ltd 38

Novartis AG 39

Otsuka Holdings Co Ltd 39

Prismic Pharmaceuticals Inc 40

Prolong Pharmaceuticals LLC 40

ProMetic Life Sciences Inc 41

Reata Pharmaceuticals Inc 41

Regulus Therapeutics Inc 42

Relypsa Inc 42

Resverlogix Corp 43

Spotlight Innovation Inc 43

Taisho Pharmaceutical Co Ltd 44

Toray Industries Inc 44

Tricida Inc 45

Unity Biotechnology Inc 45

Vascular BioSciences 46

VESSL Therapeutics Ltd 46

Vicore Pharma AB 47

Chronic Kidney Disease (Chronic Renal Failure)-Drug Profiles 48

(palmidrol + silibinin)-Drug Profile 48

ambrisentan-Drug Profile 49

ANG-3070-Drug Profile 52

ANG-3281-Drug Profile 53

ANG-3586-Drug Profile 54

Antisense RNAi Oligonucleotides for Acute Kidney Injury and Chronic Kidney Disease-Drug Profile 55

apabetalone-Drug Profile 56

AS-2444697-Drug Profile 68

bardoxolone methyl-Drug Profile 69

BI-655088-Drug Profile 75

BKE-001-Drug Profile 76

BLR-400-Drug Profile 77

C-21-Drug Profile 78

CAB-101-Drug Profile 81

calcium succinate-Drug Profile 83

CAR Peptide-Drug Profile 84

cardiotoxin-Drug Profile 85

Cell Therapy for Chronic Kidney Disease and Metabolic Disorders-Drug Profile 86

COR-001-Drug Profile 87

CXA-10-Drug Profile 88

dapagliflozin propanediol-Drug Profile 89

Drug for Kidney Diseases-Drug Profile 96

Drug to Activate sGC for Chronic Kidney Disease-Drug Profile 97

EOS-789-Drug Profile 98

F-351-Drug Profile 99

finerenone-Drug Profile 101

FM-1302-Drug Profile 103

KBP-5074-Drug Profile 104

LHW-090-Drug Profile 106

MultiGeneGraft-Drug Profile 107

NAV-003-Drug Profile 108

NZ-419-Drug Profile 109

obinutuzumab-Drug Profile 110

pacritinib-Drug Profile 118

patiromer sorbitex calcium-Drug Profile 131

PBI-4050-Drug Profile 135

Recombinant Plasma Gelsolin Replacement for Renal Disease-Drug Profile 142

Recombinant Protein to Agonize ALK and BMP Receptors for Alport Syndrome, Kidney Diseases, Metabolic Disorders and Osteoarthritis-Drug Profile 143

Sanguinate-Drug Profile 145

Small Molecule to Agonize CaSR for Chronic Kidney Disease and Primary Hyperparathyroidism-Drug Profile 148

Small Molecule to Inhibit Sodium-Phosphate Cotransporter 2b for Chronic Kidney Disease-Drug Profile 149

Small Molecule to Inhibit Soluble Epoxide Hydrolase for Chronic Kidney Disease-Drug Profile 150

Small Molecules for Chronic Kidney Disease-Drug Profile 151

Small Molecules for Chronic Kidney Disease-Drug Profile 152

SP-20103-Drug Profile 153

SPR-494-Drug Profile 154

Stem Cell Therapy for Chronic Kidney Disease-Drug Profile 155

Stem Cell Therapy for Genito Urinary System And Sex Hormone Diseases, Immunology, Metabolic Disorders, Oncology and Respiratory Disease-Drug Profile 156

Synthetic Peptide to Modulate GHSR for Chronic Kidney Disease-Drug Profile 157

tesidolumab-Drug Profile 158

tolvaptan-Drug Profile 160

torsemide ER-Drug Profile 164

TRC-101-Drug Profile 165

TS-143-Drug Profile 166

verinurad-Drug Profile 167

Vida-5-Drug Profile 169

VS-105-Drug Profile 170

Wnt-001-Drug Profile 171

YS-1402-Drug Profile 172

Chronic Kidney Disease (Chronic Renal Failure)-Dormant Projects 173

Chronic Kidney Disease (Chronic Renal Failure)-Discontinued Products 175

Chronic Kidney Disease (Chronic Renal Failure)-Product Development Milestones 176

Featured News & Press Releases 176

Appendix 190

Methodology 190

Coverage 190

Secondary Research 190

Primary Research 190

Expert Panel Validation 190

Contact Us 190

Disclaimer 191

List of Figures

Number of Products under Development for Chronic Kidney Disease (Chronic Renal Failure), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Top 10 Routes of Administration, H1 2017

Number of Products by Stage and Top 10 Routes of Administration, H1 2017

Number of Products by Top 10 Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1 2017

List of Tables

Number of Products under Development for Chronic Kidney Disease (Chronic Renal Failure), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by Angion Biomedica Corp, H1 2017

Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by apceth Biopharma GmbH, H1 2017

Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by Astellas Pharma Inc, H1 2017

Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by AstraZeneca Plc, H1 2017

Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by Bayer AG, H1 2017

Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by BLR Bio LLC, H1 2017

Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by Boehringer Ingelheim GmbH, H1 2017

Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by Boryung Pharmaceutical Co Ltd, H1 2017

Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by Cellmid Ltd, H1 2017

Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by Chugai Pharmaceutical Co Ltd, H1 2017

Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by Complexa Inc, H1 2017

Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by Corvidia Corp, H1 2017

Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by CTI BioPharma Corp, H1 2017

Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by Evotec AG, H1 2017

Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by F. Hoffmann-La Roche Ltd, H1 2017

Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by Gilead Sciences Inc, H1 2017

Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by GNI Group Ltd, H1 2017

Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by Lupin Ltd, H1 2017

Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by Navya Biologicals Pvt Ltd, H1 2017

Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by Nippon Zoki Pharmaceutical Co Ltd, H1 2017

Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by Novartis AG, H1 2017

Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by Otsuka Holdings Co Ltd, H1 2017

Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by Prismic Pharmaceuticals Inc, H1 2017

Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by Prolong Pharmaceuticals LLC, H1 2017

Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by ProMetic Life Sciences Inc, H1 2017

Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by Reata Pharmaceuticals Inc, H1 2017

Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by Regulus Therapeutics Inc, H1 2017

Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by Relypsa Inc, H1 2017

Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by Resverlogix Corp, H1 2017

Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by Spotlight Innovation Inc, H1 2017

Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by Taisho Pharmaceutical Co Ltd, H1 2017

Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by Toray Industries Inc, H1 2017

Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by Tricida Inc, H1 2017

Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by Unity Biotechnology Inc, H1 2017

Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by Vascular BioSciences, H1 2017

Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by VESSL Therapeutics Ltd, H1 2017

Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by Vicore Pharma AB, H1 2017

Chronic Kidney Disease (Chronic Renal Failure)-Dormant Projects, H1 2017

Chronic Kidney Disease (Chronic Renal Failure)-Dormant Projects, H1 2017 (Contd..1), H1 2017

Chronic Kidney Disease (Chronic Renal Failure)-Discontinued Products, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Angion Biomedica Corp, apceth Biopharma GmbH, Astellas Pharma Inc, AstraZeneca Plc, Bayer AG, BLR Bio LLC, Boehringer Ingelheim GmbH, Boryung Pharmaceutical Co Ltd, Cellmid Ltd, Chugai Pharmaceutical Co Ltd, Complexa Inc, Corvidia Corp, CTI BioPharma Corp, Evotec AG, F. Hoffmann-La Roche Ltd, Gilead Sciences Inc, GNI Group Ltd, Lupin Ltd, Navya Biologicals Pvt Ltd, Nippon Zoki Pharmaceutical Co Ltd, Novartis AG, Otsuka Holdings Co Ltd, Prismic Pharmaceuticals Inc, Prolong Pharmaceuticals LLC, ProMetic Life Sciences Inc, Reata Pharmaceuticals Inc, Regulus Therapeutics Inc, Relypsa Inc, Resverlogix Corp, Spotlight Innovation Inc, Taisho Pharmaceutical Co Ltd, Toray Industries Inc, Tricida Inc, Unity Biotechnology Inc, Vascular BioSciences, VESSL Therapeutics Ltd, Vicore Pharma AB

select a license

Single User License
USD 2000 INR 129520
Site License
USD 4000 INR 259040
Corporate User License
USD 6000 INR 388560

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com